Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Amarin ( (AMRN) ) has shared an announcement.
Amarin Corporation has appointed Peter Fishman as its new Chief Financial Officer, effective immediately. Fishman, who has been with the company since 2019, brings extensive experience in finance and has played a crucial role in Amarin’s financial strategies and transactions. His appointment is expected to support the company’s financial and business strategy moving forward.
More about Amarin
Amarin Corporation plc operates in the pharmaceutical industry, focusing on developing therapeutic solutions for the treatment of cardiovascular diseases. The company’s primary product is VASCEPA, known as VAZKEPA in some markets, which is aimed at improving cardiovascular health and expanding access across global markets.
YTD Price Performance: -46.21%
Average Trading Volume: 1,198,262
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $192.6M
For an in-depth examination of AMRN stock, go to TipRanks’ Stock Analysis page.
